Efficacy of antibody drug conjugate (ADC) by mRNA expression of targeted genes in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2

被引：0

作者：

Fujisawa, T. ^{[1
]}

Nakamura, Y. ^{[1
]}

Sakamoto, N. ^{[2
]}

Hashimoto, T. ^{[1
]}

Nagamine, M. ^{[3
]}

Kuwata, T. ^{[4
]}

Ishii, G. ^{[3
]}

Yamashita, R. ^{[5
]}

Morizane, C. ^{[6
]}

Nonomura, N. ^{[7
]}

Iwata, H. ^{[8
]}

Okano, S. ^{[9
]}

Watari, H. ^{[10
]}

Namikawa, K. ^{[11
]}

Shibuki, T. ^{[1
]}

Imai-Sumida, M. ^{[1
]}

Bando, H. ^{[1
]}

Radovich, M. ^{[12
]}

Sledge, G. ^{[13
]}

Yoshino, T. ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Promot Drug & Diagnost Dev, Kashiwa, Chiba, Japan

[2] Natl Canc Ctr Exploratory Oncol Res & Clin Trial, Div Pathol, Kashiwa, Chiba, Japan

[3] Natl Canc Ctr Hosp East, Dept Pathol & Clin Labs, Kashiwa, Chiba, Japan

[4] Natl Canc Ctr Hosp East, Dept Genet Med & Serv, Kashiwa, Chiba, Japan

[5] Natl Canc Ctr Hosp East, Div Translat Informat, Kashiwa, Chiba, Japan

[6] NCCH Natl Canc Ctr Hosp, Dept Hepatobiliary & Pancreat Oncol, Tsukiji Campus,Chuo Ku, Tokyo, Japan

[7] Osaka Univ, Fac Med, Grad Sch Med, Urol Dept, Suita, Osaka, Japan

[8] Aichi Canc Ctr Hosp, Breast Oncol Dept, Nagoya, Aichi, Japan

[9] Natl Canc Ctr Hosp East, Head & Neck Med Oncol Dept, Kashiwa, Chiba, Japan

[10] Hokkaido Univ Hosp, Hematol Oncol, Sapporo, Hokkaido, Japan

[11] NCCH Natl Canc Ctr Hosp, Dermatol Oncol Dept, Chuo Ku, Tokyo, Japan

[12] Caris Life Sci, Precis Med, Phoenix, AZ USA

[13] Caris Life Sci, Lab & Specimen Receiving, Phoenix, AZ USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2206

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

201P

引用

页码：S297 / S298

页数：2

共 50 条

[1] Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN
Saori, M.
Nakamura, Y.
Sawada, K.
Horasawa, S.
Kadowaki, S.
Kato, K.
Ueno, M.
Oki, E.
Satoh, T.
Komatsu, Y.
Tukachinsky, H.
Lee, J.
Madison, R.
Sokol, E.
Pavlick, D.
Aiyer, A.
Fabrizio, D.
Venstrom, J.
Oxnard, G.
Yoshino, T.
ANNALS OF ONCOLOGY, 2021, 32 : S390 - S391
[2] Activity on Nationwide Cancer Genome Screening Project for Advanced Solid Tumors; SCRUM-Japan GI-/MONSTAR-SCREEN
Yoshino, Takayuki
CANCER SCIENCE, 2021, 112 : 1013 - 1013
[3] SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors
Nakamura, Yoshiaki
Fujisawa, Takao
Taniguchi, Hiroya
Bando, Hideaki
Okamoto, Wataru
Tsuchihara, Katsuya
Yoshino, Takayuki
Ohtsu, Atsushi
CANCER SCIENCE, 2021, 112 (11) : 4425 - 4432
[4] Impact of MTAP loss on prognosis and efficacy of immune check point inhibitors across advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-1
Seguchi, K.
Fujisawa, T.
Ikeda, S.
Oyama, Y.
Kadowaki, S.
Morizane, C.
Ueno, M.
Oki, E.
Yamagami, W.
Yuki, S.
Nonomura, N.
Iwata, H.
Watari, H.
Okano, S.
Namikawa, K.
Bando, H.
Yoshino, T.
Nakamura, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S243 - S244
[5] Gut microbiota and efficacy of immune-checkpoint inhibitors (ICIs) in patients (pts) with advanced solid tumor: SCRUM-Japan MONSTAR-SCREEN
Sawada, K.
Yamashita, R.
Horasawa, S.
Fujisawa, T.
Yoshikawa, A.
Nakamura, Y.
Taniguchi, H.
Kadowaki, S.
Hosokawa, M.
Kodama, T.
Kato, K.
Satoh, T.
Komatsu, Y.
Shiota, M.
Yasui, H.
Yamazaki, K.
Yoshino, T.
ANNALS OF ONCOLOGY, 2021, 32 : S382 - S382
[6] Prognostic impact of HER family expressions for metastatic colorectal cancer (mCRC): SCRUM-Japan MONSTAR-SCREEN-2 and CALGB/SWOG 80405 trial (Alliance) international collaboration
Hashimoto, Tadayoshi
Nakamura, Yoshiaki
Yang, Yan
Battaglin, Francesca
Innocenti, Federico
Venook, Alan P.
Makiyama, Akitaka
Boku, Shogen
Machida, Nozomu
Takahashi, Naoki
Kadowaki, Shigenori
Komatsu, Yoshito
Kudo, Toshihiro
Oki, Eiji
Kato, Takeshi
Kagawa, Yoshinori
Fujisawa, Takao
Bando, Hideaki
Lenz, Heinz-Josef
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program
Nakamura, Yoshiaki
Yamashita, Riu
Okamoto, Wataru
Komatsu, Yoshito
Yuki, Satoshi
Ueno, Makoto
Kato, Ken
Taniguchi, Hiroya
Kagawa, Yoshinori
Denda, Tadamichi
Hara, Hiroki
Esaki, Taito
Moriwaki, Toshikazu
Sunakawa, Yu
Oki, Eiji
Nagashima, Fumio
Nishina, Tomohiro
Satoh, Taroh
Kawakami, Hisato
Yamaguchi, Kensei
Ohtsubo, Koushiro
Kato, Takeshi
Horita, Yosuke
Tsuji, Akihito
Yasui, Hisateru
Goto, Masahiro
Hamamoto, Yasuo
Wakabayashi, Masashi
Ikeno, Takashi
Shitara, Kohei
Bando, Hideaki
Tsuchihara, Katsuya
Miki, Izumi
Ichiki, Hiroko
Ohtsu, Atsushi
Yoshino, Takayuki
JCO PRECISION ONCOLOGY, 2023, 7
[8] Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK
Woodford, R.
Beygozlu, N.
Cammarota, A.
Joshi, K.
Grochot, R. M.
Williams, A.
Fontana, E.
ANNALS OF ONCOLOGY, 2024, 35 : S517 - S518
[9] A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors
Wang, Jie
Wu, Lin
Song, Zhengbo
Li, Xingya
Liu, Caigang
Liu, Tianshu
Wu, Yiwen
Zhang, Ze
Wang, Shuni
CANCER RESEARCH, 2023, 83 (08)
[10] Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors
Sharkey, Robert M.
Ocean, Allyson J.
Starodub, Alexander N.
Bardia, Aditya
Guarino, Michael
Messersmith, Wells A.
Berlin, Jordan D.
Picozzi, Vincent J.
Moroose, Rebecca
Wegener, William A.
Maliakal, Pius
Govindan, Serengulam V.
Goldenberg, David M.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →